606 related articles for article (PubMed ID: 25123086)
1. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.
Nault JC; Calderaro J; Di Tommaso L; Balabaud C; Zafrani ES; Bioulac-Sage P; Roncalli M; Zucman-Rossi J
Hepatology; 2014 Dec; 60(6):1983-92. PubMed ID: 25123086
[TBL] [Abstract][Full Text] [Related]
2. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
Cevik D; Yildiz G; Ozturk M
World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
[TBL] [Abstract][Full Text] [Related]
3. TERT promoter mutations in primary liver tumors.
Nault JC; Zucman-Rossi J
Clin Res Hepatol Gastroenterol; 2016 Feb; 40(1):9-14. PubMed ID: 26336998
[TBL] [Abstract][Full Text] [Related]
4. Telomere shortening and telomerase reactivation in dysplastic nodules of human hepatocarcinogenesis.
Oh BK; Jo Chae K; Park C; Kim K; Jung Lee W; Han KH; Nyun Park Y
J Hepatol; 2003 Nov; 39(5):786-92. PubMed ID: 14568262
[TBL] [Abstract][Full Text] [Related]
5. Telomerase activity in precancerous hepatic nodules.
Hytiroglou P; Kotoula V; Thung SN; Tsokos M; Fiel MI; Papadimitriou CS
Cancer; 1998 May; 82(10):1831-8. PubMed ID: 9587114
[TBL] [Abstract][Full Text] [Related]
6. Telomerase reverse transcriptase promoter methylation is related to a risk of recurrence in hepatocellular carcinoma.
Ko E; Jung ES; Jung G
Hepatology; 2016 Jan; 63(1):341. PubMed ID: 25847141
[No Abstract] [Full Text] [Related]
7. Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma.
Yang X; Guo X; Chen Y; Chen G; Ma Y; Huang K; Zhang Y; Zhao Q; Winkler CA; An P; Lyu J
Oncotarget; 2016 May; 7(19):27838-47. PubMed ID: 27056898
[TBL] [Abstract][Full Text] [Related]
8. Nonlinear tumor evolution from dysplastic nodules to hepatocellular carcinoma.
Joung JG; Ha SY; Bae JS; Nam JY; Gwak GY; Lee HO; Son DS; Park CK; Park WY
Oncotarget; 2017 Jan; 8(2):2076-2082. PubMed ID: 27409339
[TBL] [Abstract][Full Text] [Related]
9. Leukemia inhibitory factor receptor is a novel immunomarker in distinction of well-differentiated HCC from dysplastic nodules.
Luo Q; Zhang Y; Wang N; Jin G; Jin H; Gu D; Tao X; Huo X; Ge T; Cong W; Wang C; Qin W
Oncotarget; 2015 Mar; 6(9):6989-99. PubMed ID: 25749520
[TBL] [Abstract][Full Text] [Related]
10. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
Nault JC; Mallet M; Pilati C; Calderaro J; Bioulac-Sage P; Laurent C; Laurent A; Cherqui D; Balabaud C; Zucman-Rossi J
Nat Commun; 2013; 4():2218. PubMed ID: 23887712
[TBL] [Abstract][Full Text] [Related]
11. Latest developments in precancerous lesions of hepatocellular carcinoma.
Niu ZS; Niu XJ; Wang WH; Zhao J
World J Gastroenterol; 2016 Mar; 22(12):3305-14. PubMed ID: 27022212
[TBL] [Abstract][Full Text] [Related]
12. Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis.
Um TH; Kim H; Oh BK; Kim MS; Kim KS; Jung G; Park YN
J Hepatol; 2011 May; 54(5):939-47. PubMed ID: 21145824
[TBL] [Abstract][Full Text] [Related]
13. [Dysplastic nodule of liver versus early hepatocellular carcinoma: a clinicopathologic and prognostic study].
Chen L; Tan Y; Zeng H; Hou Y; Xu J; Zhao J; Ji Y
Zhonghua Bing Li Xue Za Zhi; 2014 May; 43(5):301-6. PubMed ID: 25030861
[TBL] [Abstract][Full Text] [Related]
14. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.
Libbrecht L; Severi T; Cassiman D; Vander Borght S; Pirenne J; Nevens F; Verslype C; van Pelt J; Roskams T
Am J Surg Pathol; 2006 Nov; 30(11):1405-11. PubMed ID: 17063081
[TBL] [Abstract][Full Text] [Related]
15. Specific patterns of PIWI-interacting small noncoding RNA expression in dysplastic liver nodules and hepatocellular carcinoma.
Rizzo F; Rinaldi A; Marchese G; Coviello E; Sellitto A; Cordella A; Giurato G; Nassa G; Ravo M; Tarallo R; Milanesi L; Destro A; Torzilli G; Roncalli M; Di Tommaso L; Weisz A
Oncotarget; 2016 Aug; 7(34):54650-54661. PubMed ID: 27429044
[TBL] [Abstract][Full Text] [Related]
16. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma.
Ki Kim S; Ueda Y; Hatano E; Kakiuchi N; Takeda H; Goto T; Shimizu T; Yoshida K; Ikura Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Uemoto S; Chiba T; Ogawa S; Marusawa H
Int J Cancer; 2016 Dec; 139(11):2512-8. PubMed ID: 27511114
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of genetic aberrations linked to tumorigenesis in regenerative nodules of liver cirrhosis.
Kim SK; Takeda H; Takai A; Matsumoto T; Kakiuchi N; Yokoyama A; Yoshida K; Kaido T; Uemoto S; Minamiguchi S; Haga H; Shiraishi Y; Miyano S; Seno H; Ogawa S; Marusawa H
J Gastroenterol; 2019 Jul; 54(7):628-640. PubMed ID: 30756187
[TBL] [Abstract][Full Text] [Related]
18. Androgen Receptor Enhances Hepatic Telomerase Reverse Transcriptase Gene Transcription After Hepatitis B Virus Integration or Point Mutation in Promoter Region.
Li CL; Li CY; Lin YY; Ho MC; Chen DS; Chen PJ; Yeh SH
Hepatology; 2019 Feb; 69(2):498-512. PubMed ID: 30070724
[TBL] [Abstract][Full Text] [Related]
19. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder.
Vail E; Zheng X; Zhou M; Yang X; Fallon JT; Epstein JI; Zhong M
Ann Diagn Pathol; 2015 Oct; 19(5):301-5. PubMed ID: 26239299
[TBL] [Abstract][Full Text] [Related]
20. Frequent somatic TERT promoter mutations and CTNNB1 mutations in hepatocellular carcinoma.
Lee SE; Chang SH; Kim WY; Lim SD; Kim WS; Hwang TS; Han HS
Oncotarget; 2016 Oct; 7(43):69267-69275. PubMed ID: 27661004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
